RxDoctor Payments Data

Hai Shao

Infectious Disease · San Diego, CANPI 1598841033

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by AbbVie at 51.4% of the total. 2025 is the largest year on record at $261, 5.1 times the $52 reported in 2019. That places this record below the midpoint for infectious disease clinicians in CA, where the typical reported total is $297.

$376in general payments, 2019–2025

Across 9 payments — averaging $41.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$194
  • La Jolla Pharmaceutical Company$122
  • CSL Behring$25
  • Merck$18
  • Viiv Healthcare Company$18
$326,435in research payments, 2019–2025

Across 18 payments — averaging $18,135 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Incyte Corporation$326K

What the payments were for

  • Food & beverage$376100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)5$194
La Jolla Pharmaceutical Company1$122
CSL Behring1$25
Merck1$18
Viiv Healthcare Company1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$376 in reported general payments places this provider in the 50th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$181,823
Medicare patients
400
Services billed
1,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →